Cardiopulmonary Bypass Equipment - Market Insights, Competitive Landscape, and Market Forecast - 2030

Cardiopulmonary Bypass Equipment Market by Product (Heart-Lung Machines, Oxygenators, Autotransfusion Systems, and Others), Application (Cardiovascular, Respiratory, Hemodialysis, and Others), End-User (Hospitals, Specialty Clinics, Dialysis Centers, and Ambulatory Surgery Centers), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2030 owing to the rising burden of cardiovascular diseases and respiratory diseases, increasing number of surgical procedures, increasing awareness and screening programs, and increase in product launches and approvals by key market players across the globe.

The cardiopulmonary bypass equipment market was valued at USD 405.18 million in 2023, growing at a CAGR of 4.14% during the forecast period from 2024 to 2030, to reach USD 516.82 million by 2030. The demand for cardiopulmonary bypass equipment is motivated by a rise in the prevalence of cardiovascular and respiratory diseases globally which has led to an increased need for surgical interventions. Conditions such as coronary artery disease, heart failure, and congenital heart defects often require complex surgeries, which are facilitated by cardiopulmonary bypass equipment. Secondly, the increasing number of surgical procedures, driven by an aging population and advancements in medical technology, has heightened the demand for cardiopulmonary bypass equipment. More surgeries translate to a greater need for reliable and efficient cardiopulmonary bypass equipment. Thirdly, growing awareness and screening programs are contributing to the early detection and diagnosis of cardiovascular and respiratory conditions. Early detection often leads to timely surgical interventions, further driving the demand for cardiopulmonary bypass equipment. Furthermore, the increase in product launches and approvals by key market players across the globe has expanded the availability and accessibility of advanced cardiopulmonary bypass equipment. Innovations in technology and design improvements are resulting in more efficient, safer, and user-friendly equipment, which enhances the adoption rates among healthcare providers during the forecast period from 2024 to 2030.

Cardiopulmonary Bypass Equipment Market Dynamics:

According to recent data provided by the British Heart Foundation (2024), globally, approximately 620 million people, or about 1 in 13 individuals, live with heart and circulatory diseases. Additionally, as per the same source, the prevalence of heart and circulatory diseases was 100 million in Europe and 340 million in Asia and Australia in 2021. Furthermore, as per the recent data provided by the British Heart Foundation (2024), coronary (ischemic) heart disease, the most commonly diagnosed worldwide, affects an estimated 200 million people globally. Approximately 110 million men and 80 million women are affected. Additionally, around 56 million women and 45 million men are stroke survivors. It is estimated that at least 13 million people worldwide live with congenital heart disease, with potentially millions more undiagnosed.

According to the World Heart Federation (2024), approximately 60 million population are affected by atrial fibrillation which is one of the most common types of irregular heartbeat, or arrhythmia. It can increase the risk of blood clots, heart failure, and stroke. Additionally, as per the same source people with atrial fibrillation are 5X times more likely to suffer a stroke.

Furthermore, according to the recent data and stats provided by the Australian Institute of Health and Welfare (2024), in 2021, more than 500,000 population were affected by atrial fibrillation.

Heart and circulatory diseases, including coronary (ischemic) heart disease, atrial fibrillation, and stroke, collectively drive the demand for cardiopulmonary bypass equipment due to their prevalence and the complexity of treatments often requiring surgical intervention. These surgeries depend heavily on cardiopulmonary bypass equipment to maintain circulatory and respiratory functions. Coronary heart disease, resulting from plaque buildup and reduced blood flow, frequently necessitates coronary artery bypass grafting (CABG), significantly boosting cardiopulmonary bypass equipment demand. Atrial fibrillation, the most common arrhythmia, increases stroke and heart failure risks, leading to surgeries like the maze procedure or catheter ablation, which also rely on cardiopulmonary bypass support. Similarly, strokes caused by blood flow blockages often require surgical interventions that depend on cardiopulmonary bypass equipment to restore circulation, further driving market growth globally.

Additionally, companies are amplifying their production of cardiopulmonary bypass equipment and securing regulatory approvals, thereby strategically expanding their market presence and driving further growth. For instance, in July 2024, Inspira™ Technologies OXY B.H.N. Ltd. received the Israeli Ministry of Health's medical devices and accessories ("AMAR") approval for the INSPIRA™ ART100, an extra-corporeal membrane oxygenation and cardiopulmonary bypass system.

Thus, the factors mentioned above are likely to boost the market for cardiopulmonary bypass equipment during the forecasted period.

However, cardiopulmonary bypass equipment can lead to various complications, including bleeding, infection, neurological deficits, renal dysfunction, and respiratory issues, and stringent regulatory concerns for product approval may hinder the future market of cardiopulmonary bypass equipment.

Cardiopulmonary Bypass Equipment Market Segment Analysis:

Cardiopulmonary Bypass Equipment Market by Product (Heart-Lung Machines, Oxygenators, Autotransfusion Systems, and Others), Application (Cardiovascular, Respiratory, Hemodialysis, and Others), End-User (Hospitals, Specialty Clinics, Dialysis Centers, and Ambulatory Surgery Centers), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product segment of the cardiopulmonary bypass equipment market, heart-lung machines are projected to hold a considerable market share in 2023. Heart-lung machines, a critical component of cardiopulmonary bypass (CPB) systems, play a pivotal role in boosting the overall market for CPB equipment by enhancing the scope and efficacy of cardiac and thoracic surgeries. These machines temporarily assume the functions of the heart and lungs, allowing for complex surgical procedures on a still and bloodless heart, which is essential for precision in surgeries such as coronary artery bypass grafting (CABG), heart valve replacements, and heart transplants. The growing prevalence of cardiovascular diseases and respiratory diseases has driven an increasing number of surgical interventions that rely on heart-lung machines. For instance, according to the latest data provided by the Australian Institute of Health and Welfare, in 2022, around 8.5 million (34%) people in Australia were estimated to have chronic respiratory conditions. Thus, as the cases of respiratory disorders and cardiovascular diseases increase so does the demand for such high-risk and intricate procedures, which also increases the need for advanced heart-lung machines, fueling the market growth. Innovations in heart-lung machine technology such as improved oxygenators, more efficient pumps, and enhanced biocompatibility have led to better patient outcomes, fewer complications, and increased acceptance among healthcare providers.

Additionally, the regulatory approvals and advancements in technology have further bolstered market growth by providing more reliable and sophisticated equipment options, thus encouraging widespread adoption. For instance, in April 2022, LivaNova received FDA 510(k) clearance for its B-Capta system integrated into the S5 heart-lung machine.

Therefore, owing to the above-mentioned factors, the heart-lung machines category is expected to generate considerable revenue thereby pushing the overall growth of the cardiopulmonary bypass equipment market during the forecast period.

North America is expected to dominate the overall cardiopulmonary bypass equipment market:

North America is expected to account for the highest proportion of the cardiopulmonary bypass equipment market in 2023, out of all regions. This can be ascribed to the increasing prevalence of cardiac disease and respiratory disease across the region, increased government initiatives coupled with increased awareness programs for cardiac and respiratory disease, and the presence of key market players engaged in mergers, acquisitions, product launches, and other market activities across the region are expected to escalate the market of cardiopulmonary bypass equipment during the forecast period.

According to recent data from the Centers for Disease Control and Prevention (2024), approximately 4.9% of adults were diagnosed with coronary heart disease in 2022. Furthermore, by 2023, an estimated 12.1 million individuals in the United States were projected to have atrial fibrillation. Additionally, each year, over 795,000 people in the U.S. experience a stroke, with around 610,000 of these being first-time strokes. Notably, nearly 185,000 of these strokes, or about one in four, occur in individuals who have previously had a stroke.

Moreover, as per the recent data provided by the Centre for Disease Control and Prevention (2024), approximately 900,000 people in the United States are affected by venous thromboembolism (VTE, a blood clot), each year. Furthermore, as per the same source, in 2022, approximately 4.6% of U.S. adults have been diagnosed with COPD, emphysema, or chronic bronchitis.

Coronary heart disease frequently leads to severe cases requiring coronary artery bypass grafting, which relies heavily on cardiopulmonary bypass equipment to maintain heart and lung function during surgery. Atrial fibrillation, with its increased risk of stroke and heart failure, often necessitates surgical procedures that depend on cardiopulmonary bypass equipment systems for stable circulation and oxygenation. Stroke, particularly in its severe forms, may require surgical interventions to restore proper blood flow, again driving the need for cardiopulmonary bypass equipment. Furthermore, venous thromboembolism, involving conditions like deep vein thrombosis and pulmonary embolism, sometimes necessitates surgical removal of clots, a procedure that also benefits from cardiopulmonary bypass equipment support. COPD patients undergoing lung volume reduction surgery or lung transplantation require cardiopulmonary bypass equipment systems to manage their circulatory and respiratory functions during complex procedures. The high incidence of these conditions is escalating the market of cardiopulmonary bypass equipment across the region.

Additionally, the awareness programs in the United States aimed at addressing cardiac diseases focus on education, prevention, and early detection also boost the market of Cardiopulmonary Bypass Equipment across the region as public awareness campaigns educate individuals about the importance of regular screenings and preventive measures. For example, February is designated as American Heart Month, during which various organizations, including the American Heart Association (AHA) and the Centers for Disease Control and Prevention (CDC), promote awareness through campaigns, events, and educational materials. These efforts emphasize the importance of heart health, risk factors, and preventive measures.

The increasing number of product development activities in the region is further going to accelerate the growth of the cardiopulmonary bypass equipment market. For example, in March 2023 the US Food and Drug Administration (FDA) granted 510(k) clearance to LivaNova’s Essenz heart-lung machine (HLM) for use in cardiopulmonary bypass (CPB) procedures.

Therefore, the above-mentioned factors are expected to bolster the growth of the cardiopulmonary bypass equipment market in North America during the forecast period.

Cardiopulmonary Bypass Equipment Market Key Players:

Some of the key market players operating in the cardiopulmonary bypass equipment market include Medtronic plc., LivaNova PLC, MAQUET Holding B.V. & Co. KG., ABIOMED, Braile Biomedica Ltda, Tianjin Medical, Terumo Corp, Senko Medical Instrument Manufacturing Co., Ltd., Technowood Corp, Sorin, MicroPort Scientific Corporation, Xenios AG, Nipro Corporation, OriGen Biomedical, Thoratec Corporation, Inspira Technologies OXY B.H.N. Ltd., Xenios AG, Boston Scientific, Cardinal Health, B. Braun, and others.

Recent Developmental Activities in the Cardiopulmonary Bypass Equipment Market:

• In May 2024, Terumo Corporation, a global leader in cardiovascular surgery technologies, announced that the U.S. Food and Drug Administration (FDA) had granted 510(k) clearance for the CDI OneView Monitoring System. This next-generation CDI Systems platform provided enhanced visibility of key patient parameters during cardiopulmonary bypass surgery
• In August 2022, the FDA awarded breakthrough privileges to Abiomed's Impella ECP expandable percutaneous heart pump.

Key Takeaways From the Cardiopulmonary Bypass Equipment Market Report Study:

• Market size analysis for current cardiopulmonary bypass equipment size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years
• Key companies dominating the cardiopulmonary bypass equipment market.
• Various opportunities available for the other competitors in the cardiopulmonary bypass equipment market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current cardiopulmonary bypass equipment market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for cardiopulmonary bypass equipment market growth in the coming future?

Target Audience who can be Benefited From This Cardiopulmonary Bypass Equipment Market Report Study:

• Cardiopulmonary bypass equipment product providers
• Research organizations and consulting companies
• Cardiopulmonary bypass equipment -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in cardiopulmonary bypass equipment
• Various end-users want to know more about the cardiopulmonary bypass equipment market and the latest technological developments in the cardiopulmonary bypass equipment market.

Frequently Asked Questions for the Cardiopulmonary Bypass Equipment Market:

1. What are cardiopulmonary bypass equipment?

Cardiopulmonary bypass (CPB) equipment provides a bloodless field for cardiac surgery and does the work of both the heart (i.e., pumps blood) and the lungs (i.e., oxygenates the blood). CPB circuit includes pumps, cannulae, tubing, reservoir, oxygenator, heat exchanger, and arterial line filter. Cardiopulmonary bypass machines are operated by perfusionists to bypass the heart and lungs during open-heart surgery.

2. What is the market for cardiopulmonary bypass equipment?

The cardiopulmonary bypass equipment market was valued at USD 405.18 million in 2023, growing at a CAGR of 4.14% during the forecast period from 2024 to 2030, to reach USD 516.82 million by 2030.

3. What are the drivers for the cardiopulmonary bypass equipment market?

The demand for cardiopulmonary bypass equipment is motivated by a rise in the prevalence of cardiovascular and respiratory diseases globally which has led to an increased need for surgical interventions. Conditions such as coronary artery disease, heart failure, and congenital heart defects often require complex surgeries, which are facilitated by cardiopulmonary bypass equipment. Secondly, the increasing number of surgical procedures, driven by an aging population and advancements in medical technology, has heightened the demand for cardiopulmonary bypass equipment. More surgeries translate to a greater need for reliable and efficient cardiopulmonary bypass equipment. Thirdly, growing awareness and screening programs are contributing to the early detection and diagnosis of cardiovascular and respiratory conditions. Early detection often leads to timely surgical interventions, further driving the demand for cardiopulmonary bypass equipment. Furthermore, the increase in product launches and approvals by key market players across the globe has expanded the availability and accessibility of advanced cardiopulmonary bypass equipment. Innovations in technology and design improvements are resulting in more efficient, safer, and user-friendly equipment, which enhances the adoption rates among healthcare providers during the forecast period from 2024 to 2030.

4. Who are the key players operating in the cardiopulmonary bypass equipment market?

Some of the key market players operating in the Cardiopulmonary Bypass Equipment market include Medtronic plc., LivaNova PLC, MAQUET Holding B.V. & Co. KG., ABIOMED, Braile Biomedica Ltda, Tianjin Medical, Terumo Corp, Senko Medical Instrument Manufacturing Co., Ltd., Technowood Corp, Sorin, MicroPort Scientific Corporation, Xenios AG, Nipro Corporation, OriGen Biomedical, Thoratec Corporation, Inspira Technologies OXY B.H.N. Ltd., Xenios AG, Boston Scientific, Cardinal Health, B. Braun, and others.

5. Which region has the highest share in the cardiopulmonary bypass equipment market?

North America is expected to account for the highest proportion of the cardiopulmonary bypass equipment market in 2023, out of all regions. This can be ascribed to the increasing prevalence of cardiac disease and respiratory disease across the region, increased government initiatives coupled with increased awareness programs for cardiac and respiratory disease, and the presence of key market players engaged in merges, acquisition, product launches, and other market activities across the region are expected to escalate the market of cardiopulmonary bypass equipment during the forecast period.


This product will be delivered within 2 business days.